Near-unicorn Prestige Biopharma eyes early-2021 IPO in South Korea
Singapore-based firm last valued at US$827m; does not say how much it is raising in IPO
Singapore
SINGAPORE-BASED Prestige Biopharma is in the midst of pursuing an initial public offering (IPO) on the Korea Exchange, with a targeted listing in early 2021, the firm's chief executive Lisa Park said in response to queries from The Business Times (BT).
Earlier on Friday, BT reported that Prestige Biopharma's Singapore-registered entity had been been fully acquired by the Korea Securities Depository (KSD), as shown in Dec 8 regulatory data on intelligence platform VentureCap Insights.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
